Research Article | Open Access
Volume 2022 - 1 | Article ID 244 | http://dx.doi.org/10.51521/IJMHR.2022.1210
Academic Editor: Darko Medin
Naresh
Lenkapothula1, Bonaspur Srivani2
1Nova College of
Pharmaceutical Education and Research, Hyderabad, Jafferguda, Hayat Nagar
(Mandal), Telangana-501512
2Nova College of
Pharmaceutical Education and Research, Hyderabad, Jafferguda, Hayat Nagar
(Mandal), Telangana-501512
Corresponding
Author:
Naresh Lenkapothula, (Pharma D), Nova College of Pharmaceutical Education and
Research, Hyderabad, Jafferguda, Hayat Nagar (Mandal), Telangana-501512,
Email: lnaresh95733@gmail.com
Citation: Naresh L,
Srivani B (2022) Glucagon-like Peptide-1 (GLP-1) Agonists: A Review.
Int J Med Healthcare Rep, 1(2); 1-3
Copyright: Naresh Lenkapothula ©
2022, This is an open-access article distributed under the terms of the
Creative Commons Attribution 4.0 International License, which permits
unrestricted use, distribution and reproduction in any medium, provided the
original author and source are credited
Diabetes mellitus (DM) is
defined as a metabolic disease and is characterized by persistent elevation of
blood glucose levels (Hyperglycemia). It is linked with abnormalities in the
metabolism of carbohydrates, fats and proteins and if this illness is untreated
over period it results in chronic complications which include Microvascular
Complications (retinopathy, nephropathy and neuropathy) and Macrovascular
complications (Coronary artery disease, Peripheral arterial disease and stroke).
These complications can be prevented by optimal management of patient with
diabetes mellitus and thereby improves quality of life. Valuable information
that was obtained from research and drug development efforts over the past
several decades has been applied directly for improving outcomes in Diabetes
mellitus patients and this broaden the therapeutic repository. In recent years
incretin has become an important target in the treatment of Type-2 Diabetes
mellitus and Glucagon like peptide-1 receptor agonists(GLP-1 RA) are known for
their role in glucose lowering effects. Glucagon like peptide-1 receptor
agonists (GLP-1 RA) are evolving as a crucial therapy to consider in Type-2
Diabetes mellitus patients and this class drugs are given because of their
ability to lower glycated haemoglobin and their associated weight loss and low
risk for hypoglycemia. In this article we review GLP-1 agonists as a treatment
of type 2 diabetes, their chemistry other effects will also be discussed
GLP-1 receptor agonists,
Diabetes mellitus, Hyperglycemia and Glycated haemoglobin
.png)
.jpg)
.gif)
.jpg)
